Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yueyu Fang"'
Autor:
Xiaofeng Chen, Hao Xu, Xiaobing Chen, Tongpeng Xu, Yitong Tian, Deqiang Wang, Fen Guo, Kangxin Wang, Guangfu Jin, Xiao Li, Rong Wang, Fengyuan Li, Yongbin Ding, Jie Tang, Yueyu Fang, Jing Zhao, Liang Liu, Ling Ma, Lijuan Meng, Zhiguo Hou, Rongrong Zheng, Yang Liu, Ni Guan, Bei Zhang, Shuang Tong, Shiqing Chen, Xing Li, Yongqian Shu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-8 (2024)
Abstract Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and phase 1b (dose expansion) study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapy for advance
Externí odkaz:
https://doaj.org/article/7a70679d73974d70be756d1e0e474fad
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Molecular biomarkers have the potential to predict the recurrence risk of early-stage lung adenocarcinoma (LUAD) after complete resection, but the study results are controversial. We aimed to clarify the association of molecular alterations
Externí odkaz:
https://doaj.org/article/7badec655df14cbaac57d984189bb82b
Autor:
Guoqun Wang, MM, Lanlan Pan, MM, Jianyi Zhao, BS, Jie Tang, MM, Yueyu Fang, MM, Hui Sun, MM, Poshita Kumari Seesaha, MM, Wensen Chen, PhD, Xiaofeng Chen, PhD
Publikováno v:
Medicine, Vol 101, Iss 25, p e29364 (2022)
Abstract. Background:. During the coronavirus disease 2019 (COVID-19) pandemic, endoscopic screening for gastrointestinal tumors was suspended or delayed in most countries. Thus, our study aimed to quantify the impact of COVID-19 on the clinical outc
Externí odkaz:
https://doaj.org/article/6ceb82eefa684116adfc2512f67c426c
Autor:
Yi, Chen, Xiao, Li, Jin, Xu, Hua, Xiao, Cuiju, Tang, Wei, Liang, Xuedan, Zhu, Yueyu, Fang, Hanjin, Wang, Junfeng, Shi
Publikováno v:
Bioengineered. 13:3526-3536
The burden of breast cancer (BC) has exacerbated over decades. Paclitaxel resistance is responsible for increasing BC treatment burden. Nuclear receptor binding SET domain-containing protein 1 (NSD1) is positively correlated with a poor prognosis in
Autor:
Yi Chen, Weiwei Tang, Xuedan Zhu, Lele Zhang, Yinxing Zhu, Hua Xiao, Jin Xu, Yueyu Fang, Xiao Li, Cuiju Tang, Junfeng Shi
Publikováno v:
Bioengineered
article-version (VoR) Version of Record
Bioengineered, Vol 12, Iss 2, Pp 11506-11519 (2021)
article-version (VoR) Version of Record
Bioengineered, Vol 12, Iss 2, Pp 11506-11519 (2021)
Breast cancer (BC) is regarded as the major cause of cancer-associated deaths in women. Paclitaxel exerts a critical impact on the chemotherapy of BC, but the resistance to paclitaxel becomes a great obstacle in treating the disease. It is reported t
Autor:
Xiaofeng Chen, Hao Xu, Deqiang Wang, Xiaobing Chen, Kangxin Wang, Guangfu Jin, Yongbin Ding, Jie Tang, Yueyu Fang, Hui Sun, Qiusheng Jiang, Lanlan Pan, Yitong Tian, Rong Wang, Tongpeng Xu, Lijuan Meng, Fengyuan Li, Yongqian Shu, Fen Guo
Publikováno v:
Journal of Clinical Oncology. 41:365-365
365 Background: The dose escalation phase was presented early, and confirmed that the recommended phase II dose (RP2D) was camrelizumab (200 mg, d1) plus apatinib (250 mg, qd), S-1(40 mg, bid, d1-14) and oxaliplatin (130 mg/m2, d1) every 3 weeks foll
Autor:
Xiaofeng Chen, Yongbin Ding, Deqiang Wang, Kangxin Wang, Hao Xu, Jie Tang, Wei Li, Yueyu Fang, Hui Sun, Liang Liu, Qiusheng Jiang, Lanlan Pan, Yitong Tian, Rong Wang, Tongpeng Xu, Lijuan Meng, Fengyuan Li, Yongqian Shu
Publikováno v:
Journal of Clinical Oncology. 40:e16053-e16053
e16053 Background: The combination of camrelizumab, an anti-PD-1 monoclonal antibody, and apatinib, a selective VEGFR-2 inhibitor, has shown synergistic antitumor effects in G/GEJ adenocarcinoma patients. We aimed to evaluate the safety and efficacy
Autor:
Yueyu Fang, Hui Sun, Yi Chen, Nanyuan Jiang, Lianhua Ji, Junfeng Shi, Fang, Yueyu, Sun, Hui, Chen, Yi, Jiang, Nanyuan, Ji, Lianhua, Shi, Junfeng
Publikováno v:
Medicine; 8/6/2021, Vol. 100 Issue 31, p1-5, 5p